ATE517101T1 - Als mmp-inhibitoren verwendete hydantoinderivate - Google Patents

Als mmp-inhibitoren verwendete hydantoinderivate

Info

Publication number: ATE517101T1
Authority: AT; Austria
Prior art keywords: derivatives used; mmp inhibitors; hydantoine; hydantoine derivatives; mmp
Prior art date: 2006-11-29

Application number

AT07824738T

Other languages

English (en)

Inventor

David Chapman

Balint Gabos

Af Rosenschold Magnus Munck

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-29

Filing date

2007-11-28

Publication date

2011-08-15

2007-11-28 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE517101T1 publication Critical patent/ATE517101T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Virology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)

AT07824738T 2006-11-29 2007-11-28 Als mmp-inhibitoren verwendete hydantoinderivate ATE517101T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86760606P	2006-11-29	2006-11-29
PCT/GB2007/004556 WO2008065393A1 (en)	2006-11-29	2007-11-28	Hydantoin derivatives used as mmp inhibitors

Publications (1)

Publication Number	Publication Date
ATE517101T1 true ATE517101T1 (de)	2011-08-15

Family

ID=38969379

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07824738T ATE517101T1 (de)	2006-11-29	2007-11-28	Als mmp-inhibitoren verwendete hydantoinderivate

Country Status (27)

Country	Link
US (2)	US8183251B2 (de)
EP (1)	EP2097406B1 (de)
JP (1)	JP5097212B2 (de)
KR (1)	KR20090083416A (de)
CN (1)	CN101541789B (de)
AR (1)	AR064041A1 (de)
AT (1)	ATE517101T1 (de)
AU (1)	AU2007327105B2 (de)
BR (1)	BRPI0719389A2 (de)
CA (1)	CA2670166A1 (de)
CL (1)	CL2007003423A1 (de)
CO (1)	CO6210692A2 (de)
EC (1)	ECSP099370A (de)
ES (1)	ES2368013T3 (de)
HK (1)	HK1133650A1 (de)
IL (1)	IL198640A0 (de)
MX (1)	MX2009005357A (de)
NO (1)	NO20092412L (de)
NZ (1)	NZ576821A (de)
PE (1)	PE20081120A1 (de)
RU (1)	RU2463301C2 (de)
SA (1)	SA07280646B1 (de)
TW (1)	TW200831488A (de)
UA (1)	UA93425C2 (de)
UY (1)	UY30748A1 (de)
WO (1)	WO2008065393A1 (de)
ZA (1)	ZA200903286B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0100902D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
SE0100903D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
SE0202539D0 (sv) *	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
SE0401762D0 (sv) *	2004-07-05	2004-07-05	Astrazeneca Ab	Novel compounds
US7648992B2 (en) *	2004-07-05	2010-01-19	Astrazeneca Ab	Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) *	2004-12-17	2004-12-17	Astrazeneca Ab	Novel componds
SE0403086D0 (sv) *	2004-12-17	2004-12-17	Astrazeneca Ab	Compounds
WO2006099598A2 (en) *	2005-03-16	2006-09-21	Sensus Metering Systems Inc.	Determining a physical location of a sensor
TW200740769A (en) *	2006-03-16	2007-11-01	Astrazeneca Ab	Novel process
TW200831488A (en)	2006-11-29	2008-08-01	Astrazeneca Ab	Novel compounds
BRPI0819831A2 (pt)	2007-11-29	2019-09-24	Boehringer Ingelheim Int	derivados de amidas de áciodo 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-carboxílico
US9186377B2 (en)	2011-06-03	2015-11-17	Maguire Abbey, Llc	Method, composition, and articles for improving joint lubrication
WO2013113787A1 (en)	2012-02-03	2013-08-08	Basf Se	Fungicidal pyrimidine compounds
WO2013113720A1 (en)	2012-02-03	2013-08-08	Basf Se	Fungicidal pyrimidine compounds
WO2013113716A1 (en)	2012-02-03	2013-08-08	Basf Se	Fungicidal pyrimidine compounds
CA2862346A1 (en)	2012-02-03	2013-08-08	Basf Se	Fungicidal pyrimidine compounds
WO2013113776A1 (en)	2012-02-03	2013-08-08	Basf Se	Fungicidal pyrimidine compounds
WO2013113773A1 (en)	2012-02-03	2013-08-08	Basf Se	Fungicidal pyrimidine compounds
AR089884A1 (es)	2012-02-03	2014-09-24	Basf Se	Compuestos fungicidas de pirimidina
WO2013135672A1 (en)	2012-03-13	2013-09-19	Basf Se	Fungicidal pyrimidine compounds
AR092971A1 (es) *	2012-10-26	2015-05-06	Lilly Co Eli	Inhibidores de agrecanasa
CN110559441A (zh) *	2013-04-22	2019-12-13	株式会社栃木临床病理研究所	抗肿瘤剂
EP2907512A1 (de)	2014-02-14	2015-08-19	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Hemmer von MMP-12 als antivirale Wirkstoffe
CN111533699B (zh) *	2020-05-27	2023-12-01	龙曦宁（上海）医药科技有限公司	一种2-（三氟甲基）嘧啶-5-醇的合成方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2327890A (en) *	1940-04-17	1943-08-24	Parke Davis & Co	Substituted phenoxyalkyl ethers
US2745875A (en) *	1953-06-30	1956-05-15	Hoechst Ag	Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) *	1966-01-05	1969-06-24	American Home Prod	5,5-disubstituted hydantoins
US3529019A (en) *	1968-04-23	1970-09-15	Colgate Palmolive Co	Alkylaryloxy alanines
US3849574A (en) *	1971-05-24	1974-11-19	Colgate Palmolive Co	Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) *	1977-09-01	1982-02-09	Science Union Et Cie	Thiosubstituted amino acids
GB1601310A (en) *	1978-05-23	1981-10-28	Lilly Industries Ltd	Aryl hydantoins
JPS6172762A (ja)	1984-09-17	1986-04-14	Kanegafuchi Chem Ind Co Ltd	光学活性ヒダントイン類の製造法
JPS61212292A (ja) *	1985-03-19	1986-09-20	Mitsui Toatsu Chem Inc	Ｄ−α−アミノ酸の製造方法
CA1325222C (en)	1985-08-23	1993-12-14	Lederle (Japan), Ltd.	Process for producing 4-biphenylylacetic acid
GB8618559D0 (en)	1986-07-30	1986-09-10	Genetics Int Inc	Rhodococcus bacterium
US4983771A (en) *	1989-09-18	1991-01-08	Hexcel Corporation	Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl)	1990-02-16	1991-09-16	Stamicarbon	Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da)	1990-07-05	1990-07-05	Novo Nordisk As	Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en)	1990-11-13	1992-08-18	Merck & Co Inc	Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) *	1991-10-30	1998-06-18	Janssen Pharmaceutica Nv	1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) *	1991-12-20	1994-05-03	Warner-Lambert Company	Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) *	1992-05-19	1993-09-21	Warner-Lambert Company	Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl)	1992-07-09	1994-02-01	Dsm Nv	Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (de)	1993-08-23	1995-03-01	Fujirebio Inc.	Hydantoinderivat als Metalloproteaseinhibitor
JPH09505310A (ja)	1993-11-16	1997-05-27	メルクエンドカンパニーインコーポレーテッド	ピペリジンショウノウスルホニルオキシトシン拮抗剤
DE69534213T2 (de)	1994-10-25	2006-01-12	Astrazeneca Ab	Therapeutisch wirksame Heterocyclen
ZA96211B (en)	1995-01-12	1996-07-26	Teva Pharma	Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) *	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
CZ291337B6 (cs) *	1995-11-22	2003-02-12	Darwin Discovery Limited	Merkaptoalkylpeptidylová sloučenina, její použití pro výrobu přípravku pro léčení nebo prevenci stavu souvisejícího s metalloproteinázou nebo TNFalfa a farmaceutický přípravek ji obsahující
GB9616643D0 (en) *	1996-08-08	1996-09-25	Chiroscience Ltd	Compounds
US5919790A (en) *	1996-10-11	1999-07-06	Warner-Lambert Company	Hydroxamate inhibitors of interleukin-1β converting enzyme
ATE212619T1 (de) *	1996-10-22	2002-02-15	Upjohn Co	Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
EP0983239A1 (de) *	1997-05-06	2000-03-08	Novo Nordisk A/S	Neue heterocyclische verbindungen
ES2165640T3 (es) *	1997-05-09	2002-03-16	Hoechst Ag	Acidos diaminocarboxilicos sustituidos.
TR199903287T2 (xx)	1997-07-31	2000-09-21	Abbott Laboratories	Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri.
TW514634B (en)	1997-10-14	2002-12-21	Lilly Co Eli	Process to make chiral compounds
SK11692000A3 (sk) *	1998-02-04	2001-02-12	Novartis Ag	Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US6329418B1 (en) *	1998-04-14	2001-12-11	The Procter & Gamble Company	Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077974A1 (de) *	1998-05-14	2001-02-28	Du Pont Pharmaceuticals Company	Substituierte aryl hydroxamsäure als metalloproteinase inhibitoren
SK18302000A3 (sk) *	1998-06-03	2001-06-11	Gpi Nil Holdings, Inc.	N-viazané sulfónamidy n-heterocyklických karboxylových kyselín a izosterov karboxylových kyselín, farmaceutický prostriedok s ich obsahom a ich použitie
EP1087937A1 (de) *	1998-06-17	2001-04-04	Du Pont Pharmaceuticals Company	Cyclische hydroxamsäuren als metalloproteinase-inhibitoren
FR2782082B3 (fr) *	1998-08-05	2000-09-22	Sanofi Sa	Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) *	1998-08-14	2002-01-15	Gpi Nil Holdings, Inc.	N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
DE69907238T2 (de)	1998-10-07	2003-11-06	Yazaki Corp., Tokio/Tokyo	Sol-gel verfahren unter verwendung poröser formen
DE69915004T2 (de) *	1998-11-05	2004-09-09	Pfizer Products Inc., Groton	5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
US6340691B1 (en) *	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CN1343219A (zh)	1999-01-28	2002-04-03	中外制药株式会社	取代的苯乙基胺衍生物
US20020006920A1 (en) *	1999-07-22	2002-01-17	Robinson Ralph Pelton	Arylsulfonylamino hydroxamic acid derivatives
DE60026404T2 (de) *	1999-08-02	2006-10-19	F. Hoffmann-La Roche Ag	Verfahren zur Herstellung von Benzothiophen-Derivaten
BR0013143A (pt) *	1999-08-12	2002-06-11	Pharmacia Italia Spa	Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
US6525202B2 (en) *	2000-07-17	2003-02-25	Wyeth	Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) *	2000-08-15	2002-05-30	Naidu B. Narasimhulu	Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) *	2000-09-08	2002-07-11	Madar David J.	Oxazolidinone antibacterial agents
EP1191024A1 (de)	2000-09-22	2002-03-27	Harald Tschesche	Thiadiazine und ihre Verwendung als Metallproteinaseinhibotoren
EE200300439A (et) *	2001-03-15	2003-12-15	Astrazeneca Ab	Metalloproteinaasi inhibiitorid
SE0100903D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
SE0100902D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
CA2447475A1 (en) *	2001-05-25	2002-12-05	Chu-Biao Xue	Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) *	2001-06-08	2001-08-01	Glaxo Group Ltd	Chemical compounds
SE0103710D0 (sv) *	2001-11-07	2001-11-07	Astrazeneca Ab	Compounds
JP4485941B2 (ja)	2002-06-05	2010-06-23	株式会社カネカ	光学活性α−メチルシステイン誘導体の製造方法
SE0202539D0 (sv) *	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
GB0221250D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
GB0221246D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
US20040266832A1 (en) *	2003-06-26	2004-12-30	Li Zheng J.	Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) *	2003-07-24	2004-08-01	Au Optronics Corp	Method for manufacturing polysilicon film
SE0400284D0 (sv)	2004-02-10	2004-02-10	Astrazeneca Ab	Novel compounds
SE0401763D0 (sv) *	2004-07-05	2004-07-05	Astrazeneca Ab	Compounds
US7648992B2 (en) *	2004-07-05	2010-01-19	Astrazeneca Ab	Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) *	2004-07-05	2004-07-05	Astrazeneca Ab	Novel compounds
SE0403085D0 (sv) *	2004-12-17	2004-12-17	Astrazeneca Ab	Novel componds
SE0403086D0 (sv) *	2004-12-17	2004-12-17	Astrazeneca Ab	Compounds
TW200740769A (en) *	2006-03-16	2007-11-01	Astrazeneca Ab	Novel process
TW200800954A (en) *	2006-03-16	2008-01-01	Astrazeneca Ab	Novel crystal modifications
TW200831488A (en)	2006-11-29	2008-08-01	Astrazeneca Ab	Novel compounds

2007
- 2007-11-26 TW TW096144755A patent/TW200831488A/zh unknown
- 2007-11-28 BR BRPI0719389-0A2A patent/BRPI0719389A2/pt not_active IP Right Cessation
- 2007-11-28 CA CA002670166A patent/CA2670166A1/en not_active Abandoned
- 2007-11-28 CN CN2007800442217A patent/CN101541789B/zh not_active Expired - Fee Related
- 2007-11-28 ES ES07824738T patent/ES2368013T3/es active Active
- 2007-11-28 MX MX2009005357A patent/MX2009005357A/es active IP Right Grant
- 2007-11-28 PE PE2007001670A patent/PE20081120A1/es not_active Application Discontinuation
- 2007-11-28 SA SA07280646A patent/SA07280646B1/ar unknown
- 2007-11-28 KR KR1020097010942A patent/KR20090083416A/ko not_active Application Discontinuation
- 2007-11-28 RU RU2009119290/04A patent/RU2463301C2/ru not_active IP Right Cessation
- 2007-11-28 AU AU2007327105A patent/AU2007327105B2/en not_active Ceased
- 2007-11-28 US US11/946,517 patent/US8183251B2/en not_active Expired - Fee Related
- 2007-11-28 EP EP07824738A patent/EP2097406B1/de active Active
- 2007-11-28 UA UAA200904629A patent/UA93425C2/ru unknown
- 2007-11-28 CL CL200703423A patent/CL2007003423A1/es unknown
- 2007-11-28 NZ NZ576821A patent/NZ576821A/en not_active IP Right Cessation
- 2007-11-28 AT AT07824738T patent/ATE517101T1/de not_active IP Right Cessation
- 2007-11-28 WO PCT/GB2007/004556 patent/WO2008065393A1/en active Application Filing
- 2007-11-28 JP JP2009538778A patent/JP5097212B2/ja not_active Expired - Fee Related
- 2007-11-29 UY UY30748A patent/UY30748A1/es not_active Application Discontinuation
- 2007-11-29 AR ARP070105317A patent/AR064041A1/es not_active Application Discontinuation
2009
- 2009-05-07 IL IL198640A patent/IL198640A0/en unknown
- 2009-05-07 CO CO09046407A patent/CO6210692A2/es not_active Application Discontinuation
- 2009-05-12 ZA ZA200903286A patent/ZA200903286B/xx unknown
- 2009-05-29 EC EC2009009370A patent/ECSP099370A/es unknown
- 2009-06-24 NO NO20092412A patent/NO20092412L/no not_active Application Discontinuation
2010
- 2010-02-11 HK HK10101574.0A patent/HK1133650A1/xx not_active IP Right Cessation
2012
- 2012-03-09 US US13/416,510 patent/US20120232101A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP5097212B2 (ja)	2012-12-12
CA2670166A1 (en)	2008-06-05
ECSP099370A (es)	2009-06-30
SA07280646B1 (ar)	2010-10-05
MX2009005357A (es)	2009-06-05
CL2007003423A1 (es)	2008-07-18
US8183251B2 (en)	2012-05-22
CN101541789B (zh)	2013-02-20
NZ576821A (en)	2011-05-27
UA93425C2 (ru)	2011-02-10
US20120232101A1 (en)	2012-09-13
TW200831488A (en)	2008-08-01
UY30748A1 (es)	2008-07-03
ZA200903286B (en)	2010-10-27
RU2463301C2 (ru)	2012-10-10
AU2007327105A1 (en)	2008-06-05
KR20090083416A (ko)	2009-08-03
HK1133650A1 (en)	2010-04-01
EP2097406A1 (de)	2009-09-09
IL198640A0 (en)	2010-02-17
CN101541789A (zh)	2009-09-23
WO2008065393A1 (en)	2008-06-05
AU2007327105B2 (en)	2011-05-26
BRPI0719389A2 (pt)	2014-10-07
US20080221139A1 (en)	2008-09-11
EP2097406B1 (de)	2011-07-20
RU2009119290A (ru)	2011-01-10
PE20081120A1 (es)	2008-10-11
JP2010511027A (ja)	2010-04-08
AR064041A1 (es)	2009-03-11
NO20092412L (no)	2009-08-19
ES2368013T3 (es)	2011-11-11
CO6210692A2 (es)	2010-10-20

Publication	Publication Date	Title
ATE517101T1 (de)	2011-08-15	Als mmp-inhibitoren verwendete hydantoinderivate
ATE510825T1 (de)	2011-06-15	Acylaminopyrazole als fgfr-inhibitoren
EP2170076A4 (de)	2011-09-07	4-carboxybenzylamino-derivate als histondeacetylase-hemmer
ATE478064T1 (de)	2010-09-15	Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
ATE485268T1 (de)	2010-11-15	Pyrrolidin-derivate als erk-hemmer
DE602007008837D1 (de)	2010-10-14	Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
DE602006011363D1 (de)	2010-02-04	Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE543816T1 (de)	2012-02-15	Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
ATE549340T1 (de)	2012-03-15	Spiroindolinon-derivate als mdm2-p53 inhibitoren
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
ATE400271T1 (de)	2008-07-15	Aryl-pyridinderivate als 11-beta-hsd1-hemmer
BRPI0719204A2 (pt)	2014-03-04	Inibidores de hdac
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
ATE467623T1 (de)	2010-05-15	Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
DOP2007000084A (es)	2007-12-31	Derivados de dihidropirazolopirimidinona
BRPI0717460A2 (pt)	2013-12-24	Composições de inibidores de chk1
DK1989206T3 (da)	2012-10-08	E1-aktiveringsenzymhæmmere
BRPI0720547A2 (pt)	2014-05-06	Inibidores de metaloprotease derivada de heterocíclico
ATE420076T1 (de)	2009-01-15	Indozolonderivate als 11b-hsd1-inhibitoren
NO20085127L (no)	2009-01-08	Leptomycinderivater
ATE506358T1 (de)	2011-05-15	2-benzylpyridazinonderivate als met-kinasehemmer
CR10562A (es)	2009-03-20	Nuevos derivados de piridazina

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties